Home/Pipeline/Next-gen AID with EOFlow

Next-gen AID with EOFlow

Type 1 Diabetes

Co-developmentActive

Key Facts

Indication

Type 1 Diabetes

Phase

Co-development

Status

Active

Company

Diabeloop

About Diabeloop

Diabeloop is a Grenoble-based medtech pioneer commercializing a CE-marked and FDA-authorized AID system (DBLG2) for Type 1 diabetes, powered by a self-learning AI algorithm. The company has secured significant funding (€70M Series C in 2022) and established key international partnerships with major diabetes care players like Roche, Terumo, and Novo Nordisk to drive expansion. Its strategy focuses on interoperability, extending its AI platform to connected insulin pens for Type 2 diabetes, and pursuing global market access in the US, Japan, and Korea.

View full company profile

Therapeutic Areas

Metabolic

Other Type 1 Diabetes Drugs

Drug	Company	Phase	Status
eRapa	Biodexa Pharmaceuticals	Preclinical	Research
ImmCelz™	Creative Medical Technology Holdings	Clinical Trial	Active
Adimune (ADi-001/002)	Aditxt	Preclinical / Early Clinical	Active
MSC‑Diabetes	Advancells	Phase 1	Active
BioChaperone® Lispro (THDB0206)	Adocia	Phase 3	Active
AdoShell® Islet Cell Therapy	Adocia	Preclinical	Platform Development
Pediatric Indications (<2 years)	Tandem Diabetes	Research	Exploratory
Icovamenib (BMF-219)	Biomea Fusion	Phase 2	Completed Follow-up, Data Pending
Undisclosed Novel Strategy	CG Scientific	Pre-clinical	Early Research
Sotagliflozin	Lexicon Pharmaceuticals	Phase 3	Regulatory Path Uncertain
Stem Cell-Derived Beta Cells	BioTalentum	Pre-clinical	Active
NICHE	Continuity Biosciences	Pre-clinical	Active